Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

NNC0519-0130

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Novo Nordisk · Phase 2 · Recruiting · Enrollment 465

NCT06717698

ArmPopulationDoseWeeksEstimandWeight change
Dosing scheme a: NNC0519-0130Chronic Kidney Diseasen/r43n/rn/r
Dosing scheme a: PlaceboChronic Kidney Diseasen/r43n/rn/r
Dosing scheme b: NNC0519-0130Chronic Kidney Diseasen/r43n/rn/r
Dosing scheme b: PlaceboChronic Kidney Diseasen/r43n/rn/r
Dosing scheme c: NNC0519-0130Chronic Kidney Diseasen/r43n/rn/r
Dosing scheme c: PlaceboChronic Kidney Diseasen/r43n/rn/r
Dosing scheme d: NNC0519-0130Chronic Kidney Diseasen/r43n/rn/r
Dosing scheme d: PlaceboChronic Kidney Diseasen/r43n/rn/r
Dosing scheme e: SemaglutideChronic Kidney Diseasen/r43n/rn/r